A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05650632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B and Arms C \& D. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of etentamig (ABBV-383). In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of etentamig (ABBV-383). In Arm B a flat dose of etentamig (ABBV-383) will be tested. In Arms C \& D, the step-up dose identified in Arm A will be used followed by the target dose of etentamig (ABBV-383) to investigate outpatient administration of etentamig (ABBV-383). Around 210 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 50 sites across the world. Participants will receive etentamig (ABBV-383) as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Study identification
- NCT ID
- NCT05650632
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 21, 2023 (Actual)
- Primary completion
- Aug 2029 (Estimated)
- Completion
- Aug 2029 (Estimated)
- Last update posted
- Jul 13, 2026
2023 – 2029
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona /ID# 251405 | Phoenix | Arizona | 85054 | Recruiting |
| Highlands Oncology Group - Springdale /ID# 267742 | Springdale | Arkansas | 72762 | Recruiting |
| Rocky Mountain Cancer Centers - Aurora /ID# 268574 | Aurora | Colorado | 80012 | Recruiting |
| Medical Oncology Hematology Consultants /ID# 268560 | Newark | Delaware | 19713 | Recruiting |
| Hope And Healing Cancer Services /ID# 268536 | Hinsdale | Illinois | 60521 | Recruiting |
| Fort Wayne Medical Oncology And Hematology /ID# 268179 | Fort Wayne | Indiana | 46804 | Recruiting |
| Franciscan St. Francis Health /ID# 280928 | Indianapolis | Indiana | 46237 | Recruiting |
| Tulane University School of Medicine /ID# 251204 | New Orleans | Louisiana | 70112 | Recruiting |
| Maryland Oncology Hematology - Silver Spring /ID# 268562 | Silver Spring | Maryland | 20904 | Not yet recruiting |
| Mayo Clinic - Rochester /ID# 251164 | Rochester | Minnesota | 55905-0001 | Recruiting |
| NHO Revive Research Institute, LLC /ID# 267869 | Lincoln | Nebraska | 68506 | Recruiting |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497 | Omaha | Nebraska | 68130 | Recruiting |
| Mt Sinai /ID# 251166 | New York | New York | 10029-6542 | Recruiting |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167 | New York | New York | 10065-6007 | Recruiting |
| University of North Carolina /ID# 251203 | Chapel Hill | North Carolina | 27514 | Recruiting |
| Atrium Health Wake Forest Baptist Medical Center /ID# 251165 | Winston-Salem | North Carolina | 27157 | Recruiting |
| University Of Cincinnati Medical Center /ID# 251746 | Cincinnati | Ohio | 45219 | Recruiting |
| Willamette Valley Cancer Institute and Research Center /ID# 267088 | Eugene | Oregon | 97401 | Recruiting |
| Baptist Memorial Hospital /ID# 280677 | Memphis | Tennessee | 38120 | Not yet recruiting |
| Vanderbilt Ingram Cancer Center /ID# 252470 | Nashville | Tennessee | 37232-0021 | Recruiting |
| Texas Oncology - Central/South Texas /ID# 268563 | Austin | Texas | 78705 | Recruiting |
| Texas Oncology - Dallas - Worth Street /ID# 280064 | Dallas | Texas | 75246 | Recruiting |
| Oncology Consultants /ID# 268323 | Houston | Texas | 77030 | Recruiting |
| Texas Oncology - Northeast Texas /ID# 268877 | Tyler | Texas | 75702 | Recruiting |
| Virginia Cancer Specialists - Fairfax /ID# 268559 | Fairfax | Virginia | 22031 | Recruiting |
| Fred Hutchinson Cancer Center. /ID# 267940 | Seattle | Washington | 98109-4405 | Recruiting |
| Northwest Medical Specialties Tacoma /ID# 267117 | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05650632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05650632 live on ClinicalTrials.gov.